Cytapheresis for the Treatment of Myeloperoxidase Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Report of Five Cases
: To minimize the adverse effects of high‐dose administration of steroids and cyclophosphamide in patients with myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA), granulocytapheresis (GCAP) or leukocytapheresis (LCAP) was performed to reduce inflammation. Four patients with rapidly pr...
Gespeichert in:
| Veröffentlicht in: | Therapeutic apheresis 2002-12, Vol.6 (6), p.443-449 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 449 |
|---|---|
| container_issue | 6 |
| container_start_page | 443 |
| container_title | Therapeutic apheresis |
| container_volume | 6 |
| creator | Hasegawa, Midori Kawamura, Nahoko Kasugai, Masami Koide, Sigehisa Murase, Masamitsu Asano, Sinsuke Toba, Takako Kushimoto, Hiroko Murakami, Kazutaka Tomita, Makoto Shikano, Masahiko Sugiyama, Satoshi |
| description | : To minimize the adverse effects of high‐dose administration of steroids and cyclophosphamide in patients with myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA), granulocytapheresis (GCAP) or leukocytapheresis (LCAP) was performed to reduce inflammation. Four patients with rapidly progressive glomerulonephritis (RPGN) and one patient with pulmonary hemorrhage due to MPO‐ANCA‐associated vasculitis were treated by cytapheresis. The prednisolone (PSL) dose was 0.28 ± 0.15 mg/kg/day (mean ± SD) (range 0.18–0.50 g/kg/day). In the 4 RPGN patients, the peak serum creatinine level was 3.7 ± 1.9 mg/dl (range 1.7 to 5.6 mg/dl). GCAP was performed in 3 RPGN patients and in 1 pulmonary hemorrhage patient. LCAP was performed in 1 RPGN patient. In the 4 RPGN patients, renal function improved after combined therapy with cytapheresis and corticosteroids. In the pulmonary hemorrhage patient, evidence of pulmonary hemorrhage on chest computed tomography scanning diminished after combined therapy with cytapheresis and corticosteroids. Cytapheresis, when combined with a low‐dose or intermediate‐dose PSL regimen, is effective in the treatment of ANCA‐associated vasculitis. |
| doi_str_mv | 10.1046/j.1526-0968.2002.00462.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72733027</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72733027</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4042-9cd89f0ac0f536edf915c2b786bac90abe8b8bf3c32ac28b115c0d5338a169093</originalsourceid><addsrcrecordid>eNqNUctu1DAUtRCItgO_gLJil_Q6ThwbsZmOaEFqAcEAS8txbjQeknGwPTDZIfVP-RIyD5Utm3uvfB6WziEkoZBRKPjlOqNlzlOQXGQ5QJ7B9Jpnu0fk_AF4PN0gaco5hzNyEcIagFayEE_JGc0LDgWIc3K_GKMeVugx2JC0zidxhcnSo449bmLi2uRuxM4N6N3ONjpgMt9Eu8Ft9G5Y2S6ZDNzQ6dBbc4Bq14zpPARnrI7YJF91MNvORhteJZ9wcP5gem1_4p_f94vJMDwjT1rdBXx-2jPy5frNcvE2vf1w824xv01NAUWeStMI2YI20JaMY9NKWpq8rgSvtZGgaxS1qFtmWK5NLmo6wdCUjAlNuQTJZuTl0Xfw7scWQ1S9DQa7Tm_QbYOq8ooxmMaMiCPReBeCx1YN3vbaj4qC2heg1mqfs9rnrPYFqEMBajdJX5z-2NY9Nv-Ep8Qnwusj4ZftcPxvY7Wcf5yOSZ4e5TZE3D3Itf-ueMWqUn17f6M-X0FxtZR3SrK_QPOnTA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72733027</pqid></control><display><type>article</type><title>Cytapheresis for the Treatment of Myeloperoxidase Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Report of Five Cases</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Hasegawa, Midori ; Kawamura, Nahoko ; Kasugai, Masami ; Koide, Sigehisa ; Murase, Masamitsu ; Asano, Sinsuke ; Toba, Takako ; Kushimoto, Hiroko ; Murakami, Kazutaka ; Tomita, Makoto ; Shikano, Masahiko ; Sugiyama, Satoshi</creator><creatorcontrib>Hasegawa, Midori ; Kawamura, Nahoko ; Kasugai, Masami ; Koide, Sigehisa ; Murase, Masamitsu ; Asano, Sinsuke ; Toba, Takako ; Kushimoto, Hiroko ; Murakami, Kazutaka ; Tomita, Makoto ; Shikano, Masahiko ; Sugiyama, Satoshi</creatorcontrib><description>: To minimize the adverse effects of high‐dose administration of steroids and cyclophosphamide in patients with myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA), granulocytapheresis (GCAP) or leukocytapheresis (LCAP) was performed to reduce inflammation. Four patients with rapidly progressive glomerulonephritis (RPGN) and one patient with pulmonary hemorrhage due to MPO‐ANCA‐associated vasculitis were treated by cytapheresis. The prednisolone (PSL) dose was 0.28 ± 0.15 mg/kg/day (mean ± SD) (range 0.18–0.50 g/kg/day). In the 4 RPGN patients, the peak serum creatinine level was 3.7 ± 1.9 mg/dl (range 1.7 to 5.6 mg/dl). GCAP was performed in 3 RPGN patients and in 1 pulmonary hemorrhage patient. LCAP was performed in 1 RPGN patient. In the 4 RPGN patients, renal function improved after combined therapy with cytapheresis and corticosteroids. In the pulmonary hemorrhage patient, evidence of pulmonary hemorrhage on chest computed tomography scanning diminished after combined therapy with cytapheresis and corticosteroids. Cytapheresis, when combined with a low‐dose or intermediate‐dose PSL regimen, is effective in the treatment of ANCA‐associated vasculitis.</description><identifier>ISSN: 1091-6660</identifier><identifier>EISSN: 1526-0968</identifier><identifier>DOI: 10.1046/j.1526-0968.2002.00462.x</identifier><identifier>PMID: 12460408</identifier><language>eng</language><publisher>Boston, MA, USA: Blackwell Science Inc</publisher><subject>Aged ; Antibodies, Antineutrophil Cytoplasmic - blood ; Autoantibodies - blood ; Autoimmune Diseases - therapy ; Cytapheresis ; Female ; Glomerulonephritis - etiology ; Glomerulonephritis - immunology ; Glomerulonephritis - therapy ; Glucocorticoids - therapeutic use ; Granulocytapheresis ; Granulocytes ; Humans ; Leukapheresis ; Lung Diseases - immunology ; Lung Diseases - therapy ; Lymphocytapheresis ; Male ; Middle Aged ; Myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis ; Peroxidase - immunology ; Prednisolone - therapeutic use ; Vasculitis - complications ; Vasculitis - immunology ; Vasculitis - therapy</subject><ispartof>Therapeutic apheresis, 2002-12, Vol.6 (6), p.443-449</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4042-9cd89f0ac0f536edf915c2b786bac90abe8b8bf3c32ac28b115c0d5338a169093</citedby><cites>FETCH-LOGICAL-c4042-9cd89f0ac0f536edf915c2b786bac90abe8b8bf3c32ac28b115c0d5338a169093</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1526-0968.2002.00462.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1526-0968.2002.00462.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12460408$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hasegawa, Midori</creatorcontrib><creatorcontrib>Kawamura, Nahoko</creatorcontrib><creatorcontrib>Kasugai, Masami</creatorcontrib><creatorcontrib>Koide, Sigehisa</creatorcontrib><creatorcontrib>Murase, Masamitsu</creatorcontrib><creatorcontrib>Asano, Sinsuke</creatorcontrib><creatorcontrib>Toba, Takako</creatorcontrib><creatorcontrib>Kushimoto, Hiroko</creatorcontrib><creatorcontrib>Murakami, Kazutaka</creatorcontrib><creatorcontrib>Tomita, Makoto</creatorcontrib><creatorcontrib>Shikano, Masahiko</creatorcontrib><creatorcontrib>Sugiyama, Satoshi</creatorcontrib><title>Cytapheresis for the Treatment of Myeloperoxidase Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Report of Five Cases</title><title>Therapeutic apheresis</title><addtitle>Therapeutic Apheresis</addtitle><description>: To minimize the adverse effects of high‐dose administration of steroids and cyclophosphamide in patients with myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA), granulocytapheresis (GCAP) or leukocytapheresis (LCAP) was performed to reduce inflammation. Four patients with rapidly progressive glomerulonephritis (RPGN) and one patient with pulmonary hemorrhage due to MPO‐ANCA‐associated vasculitis were treated by cytapheresis. The prednisolone (PSL) dose was 0.28 ± 0.15 mg/kg/day (mean ± SD) (range 0.18–0.50 g/kg/day). In the 4 RPGN patients, the peak serum creatinine level was 3.7 ± 1.9 mg/dl (range 1.7 to 5.6 mg/dl). GCAP was performed in 3 RPGN patients and in 1 pulmonary hemorrhage patient. LCAP was performed in 1 RPGN patient. In the 4 RPGN patients, renal function improved after combined therapy with cytapheresis and corticosteroids. In the pulmonary hemorrhage patient, evidence of pulmonary hemorrhage on chest computed tomography scanning diminished after combined therapy with cytapheresis and corticosteroids. Cytapheresis, when combined with a low‐dose or intermediate‐dose PSL regimen, is effective in the treatment of ANCA‐associated vasculitis.</description><subject>Aged</subject><subject>Antibodies, Antineutrophil Cytoplasmic - blood</subject><subject>Autoantibodies - blood</subject><subject>Autoimmune Diseases - therapy</subject><subject>Cytapheresis</subject><subject>Female</subject><subject>Glomerulonephritis - etiology</subject><subject>Glomerulonephritis - immunology</subject><subject>Glomerulonephritis - therapy</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Granulocytapheresis</subject><subject>Granulocytes</subject><subject>Humans</subject><subject>Leukapheresis</subject><subject>Lung Diseases - immunology</subject><subject>Lung Diseases - therapy</subject><subject>Lymphocytapheresis</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis</subject><subject>Peroxidase - immunology</subject><subject>Prednisolone - therapeutic use</subject><subject>Vasculitis - complications</subject><subject>Vasculitis - immunology</subject><subject>Vasculitis - therapy</subject><issn>1091-6660</issn><issn>1526-0968</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUctu1DAUtRCItgO_gLJil_Q6ThwbsZmOaEFqAcEAS8txbjQeknGwPTDZIfVP-RIyD5Utm3uvfB6WziEkoZBRKPjlOqNlzlOQXGQ5QJ7B9Jpnu0fk_AF4PN0gaco5hzNyEcIagFayEE_JGc0LDgWIc3K_GKMeVugx2JC0zidxhcnSo449bmLi2uRuxM4N6N3ONjpgMt9Eu8Ft9G5Y2S6ZDNzQ6dBbc4Bq14zpPARnrI7YJF91MNvORhteJZ9wcP5gem1_4p_f94vJMDwjT1rdBXx-2jPy5frNcvE2vf1w824xv01NAUWeStMI2YI20JaMY9NKWpq8rgSvtZGgaxS1qFtmWK5NLmo6wdCUjAlNuQTJZuTl0Xfw7scWQ1S9DQa7Tm_QbYOq8ooxmMaMiCPReBeCx1YN3vbaj4qC2heg1mqfs9rnrPYFqEMBajdJX5z-2NY9Nv-Ep8Qnwusj4ZftcPxvY7Wcf5yOSZ4e5TZE3D3Itf-ueMWqUn17f6M-X0FxtZR3SrK_QPOnTA</recordid><startdate>200212</startdate><enddate>200212</enddate><creator>Hasegawa, Midori</creator><creator>Kawamura, Nahoko</creator><creator>Kasugai, Masami</creator><creator>Koide, Sigehisa</creator><creator>Murase, Masamitsu</creator><creator>Asano, Sinsuke</creator><creator>Toba, Takako</creator><creator>Kushimoto, Hiroko</creator><creator>Murakami, Kazutaka</creator><creator>Tomita, Makoto</creator><creator>Shikano, Masahiko</creator><creator>Sugiyama, Satoshi</creator><general>Blackwell Science Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200212</creationdate><title>Cytapheresis for the Treatment of Myeloperoxidase Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Report of Five Cases</title><author>Hasegawa, Midori ; Kawamura, Nahoko ; Kasugai, Masami ; Koide, Sigehisa ; Murase, Masamitsu ; Asano, Sinsuke ; Toba, Takako ; Kushimoto, Hiroko ; Murakami, Kazutaka ; Tomita, Makoto ; Shikano, Masahiko ; Sugiyama, Satoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4042-9cd89f0ac0f536edf915c2b786bac90abe8b8bf3c32ac28b115c0d5338a169093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Aged</topic><topic>Antibodies, Antineutrophil Cytoplasmic - blood</topic><topic>Autoantibodies - blood</topic><topic>Autoimmune Diseases - therapy</topic><topic>Cytapheresis</topic><topic>Female</topic><topic>Glomerulonephritis - etiology</topic><topic>Glomerulonephritis - immunology</topic><topic>Glomerulonephritis - therapy</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Granulocytapheresis</topic><topic>Granulocytes</topic><topic>Humans</topic><topic>Leukapheresis</topic><topic>Lung Diseases - immunology</topic><topic>Lung Diseases - therapy</topic><topic>Lymphocytapheresis</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis</topic><topic>Peroxidase - immunology</topic><topic>Prednisolone - therapeutic use</topic><topic>Vasculitis - complications</topic><topic>Vasculitis - immunology</topic><topic>Vasculitis - therapy</topic><toplevel>online_resources</toplevel><creatorcontrib>Hasegawa, Midori</creatorcontrib><creatorcontrib>Kawamura, Nahoko</creatorcontrib><creatorcontrib>Kasugai, Masami</creatorcontrib><creatorcontrib>Koide, Sigehisa</creatorcontrib><creatorcontrib>Murase, Masamitsu</creatorcontrib><creatorcontrib>Asano, Sinsuke</creatorcontrib><creatorcontrib>Toba, Takako</creatorcontrib><creatorcontrib>Kushimoto, Hiroko</creatorcontrib><creatorcontrib>Murakami, Kazutaka</creatorcontrib><creatorcontrib>Tomita, Makoto</creatorcontrib><creatorcontrib>Shikano, Masahiko</creatorcontrib><creatorcontrib>Sugiyama, Satoshi</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Therapeutic apheresis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hasegawa, Midori</au><au>Kawamura, Nahoko</au><au>Kasugai, Masami</au><au>Koide, Sigehisa</au><au>Murase, Masamitsu</au><au>Asano, Sinsuke</au><au>Toba, Takako</au><au>Kushimoto, Hiroko</au><au>Murakami, Kazutaka</au><au>Tomita, Makoto</au><au>Shikano, Masahiko</au><au>Sugiyama, Satoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cytapheresis for the Treatment of Myeloperoxidase Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Report of Five Cases</atitle><jtitle>Therapeutic apheresis</jtitle><addtitle>Therapeutic Apheresis</addtitle><date>2002-12</date><risdate>2002</risdate><volume>6</volume><issue>6</issue><spage>443</spage><epage>449</epage><pages>443-449</pages><issn>1091-6660</issn><eissn>1526-0968</eissn><abstract>: To minimize the adverse effects of high‐dose administration of steroids and cyclophosphamide in patients with myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA), granulocytapheresis (GCAP) or leukocytapheresis (LCAP) was performed to reduce inflammation. Four patients with rapidly progressive glomerulonephritis (RPGN) and one patient with pulmonary hemorrhage due to MPO‐ANCA‐associated vasculitis were treated by cytapheresis. The prednisolone (PSL) dose was 0.28 ± 0.15 mg/kg/day (mean ± SD) (range 0.18–0.50 g/kg/day). In the 4 RPGN patients, the peak serum creatinine level was 3.7 ± 1.9 mg/dl (range 1.7 to 5.6 mg/dl). GCAP was performed in 3 RPGN patients and in 1 pulmonary hemorrhage patient. LCAP was performed in 1 RPGN patient. In the 4 RPGN patients, renal function improved after combined therapy with cytapheresis and corticosteroids. In the pulmonary hemorrhage patient, evidence of pulmonary hemorrhage on chest computed tomography scanning diminished after combined therapy with cytapheresis and corticosteroids. Cytapheresis, when combined with a low‐dose or intermediate‐dose PSL regimen, is effective in the treatment of ANCA‐associated vasculitis.</abstract><cop>Boston, MA, USA</cop><pub>Blackwell Science Inc</pub><pmid>12460408</pmid><doi>10.1046/j.1526-0968.2002.00462.x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1091-6660 |
| ispartof | Therapeutic apheresis, 2002-12, Vol.6 (6), p.443-449 |
| issn | 1091-6660 1526-0968 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72733027 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE |
| subjects | Aged Antibodies, Antineutrophil Cytoplasmic - blood Autoantibodies - blood Autoimmune Diseases - therapy Cytapheresis Female Glomerulonephritis - etiology Glomerulonephritis - immunology Glomerulonephritis - therapy Glucocorticoids - therapeutic use Granulocytapheresis Granulocytes Humans Leukapheresis Lung Diseases - immunology Lung Diseases - therapy Lymphocytapheresis Male Middle Aged Myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis Peroxidase - immunology Prednisolone - therapeutic use Vasculitis - complications Vasculitis - immunology Vasculitis - therapy |
| title | Cytapheresis for the Treatment of Myeloperoxidase Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Report of Five Cases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T17%3A08%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cytapheresis%20for%20the%20Treatment%20of%20Myeloperoxidase%20Antineutrophil%20Cytoplasmic%20Antibody-Associated%20Vasculitis:%20Report%20of%20Five%E2%80%83Cases&rft.jtitle=Therapeutic%20apheresis&rft.au=Hasegawa,%20Midori&rft.date=2002-12&rft.volume=6&rft.issue=6&rft.spage=443&rft.epage=449&rft.pages=443-449&rft.issn=1091-6660&rft.eissn=1526-0968&rft_id=info:doi/10.1046/j.1526-0968.2002.00462.x&rft_dat=%3Cproquest_cross%3E72733027%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72733027&rft_id=info:pmid/12460408&rfr_iscdi=true |